Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Insider and Institutional Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Gain Therapeutics and Esperion Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -201.44% | -136.24% |
| Esperion Therapeutics | 0.12% | -0.14% | 0.12% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Esperion Therapeutics | 1 | 6 | 1 | 0 | 2.00 |
Gain Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 400.00%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 77.00%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Esperion Therapeutics.
Risk & Volatility
Gain Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Earnings and Valuation
This table compares Gain Therapeutics and Esperion Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 1,450.10 | -$20.16 million | ($0.58) | -2.93 |
| Esperion Therapeutics | $403.14 million | 2.00 | -$22.68 million | ($0.06) | -52.17 |
Gain Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
